Format

Send to

Choose Destination
Thyroid. 2019 Apr;29(4):461-470. doi: 10.1089/thy.2018.0597.

Controversies, Consensus, and Collaboration in the Use of 131I Therapy in Differentiated Thyroid Cancer: A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association.

Author information

1
1 Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York.
2
2 Evidence and Quality, Society of Nuclear Medicine and Molecular Imaing, Reston, Virginia.
3
3 Division of Nuclear Medicine, Department of Radiology, University of Michigan Medical Center, Ann Arbor, Michigan.
4
4 Division of Endocrinology, Mayo Clinic College of Medicine, Jacksonville, Florida.
5
5 Department of Nuclear Medicine, University Hospital of Martinique, Fort de France, Martinique.
6
6 University of Antilles, Pointe-à-Pitre, Guadeloupe.
7
7 Thyroid Unit, Massachusetts General Hospital, Boston, Massachusetts.
8
8 Department of Nuclear Medicine, Northwestern Memorial Hospital, Chicago, Illinois.
9
9 Department of Physics, Royal Marsden Hospital and Institute of Cancer Research, Sutton, United Kingdom.
10
10 Department of Endocrinology and Metabolism, University Hospital Essen, Essen, Germany.
11
11 Clinic of Nuclear Medicine and Thyroid Center, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
12
12 Clinic for Nuclear Medicine, University of Zürich, Zürich, Switzerland.
13
13 North Augusta, South Carolina.
14
14 Department of Nuclear Medicine, University Hospital Marburg, Marburg, Germany.
15
15 Department of Nuclear Medicine, University Hospital Brussels (UZ Brussel, VUB), Brussels, Belgium.
16
16 European Association of Nuclear Medicine, Vienna, Austria.
17
17 Department of Endocrinology, Radboud University Medical Center, Nijmegen, The Netherlands.
18
18 Georgetown University School of Medicine, Washington Hospital Center, Washington, DC.
19
19 Department of Endocrinology and Metabolism, Odense University Hospital, Odense, Denmark.

Abstract

BACKGROUND:

Publication of the 2015 American Thyroid Association (ATA) management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer was met with disagreement by the extended nuclear medicine community with regard to some of the recommendations related to the diagnostic and therapeutic use of radioiodine (131I). Because of these concerns, the European Association of Nuclear Medicine and the Society of Nuclear Medicine and Molecular Imaging declined to endorse the ATA guidelines. As a result of these differences in opinion, patients and clinicians risk receiving conflicting advice with regard to several key thyroid cancer management issues.

SUMMARY:

To address some of the differences in opinion and controversies associated with the therapeutic uses of 131I in differentiated thyroid cancer constructively, the ATA, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association each sent senior leadership and subject-matter experts to a two-day interactive meeting. The goals of this first meeting were to (i) formalize the dialogue and activities between the four societies; (ii) discuss indications for 131I adjuvant treatment; (iii) define the optimal prescribed activity of 131I for adjuvant treatment; and (iv) clarify the definition and classification of 131I-refractory thyroid cancer.

CONCLUSION:

By fostering an open, productive, and evidence-based discussion, the Martinique meeting restored trust, confidence, and a sense of collegiality between individuals and organizations that are committed to optimal thyroid disease management. The result of this first meeting is a set of nine principles (The Martinique Principles) that (i) describe a commitment to proactive, purposeful, and inclusive interdisciplinary cooperation; (ii) define the goals of 131I therapy as remnant ablation, adjuvant treatment, or treatment of known disease; (iii) describe the importance of evaluating postoperative disease status and multiple other factors beyond clinicopathologic staging in 131I therapy decision making; (iv) recognize that the optimal administered activity of 131I adjuvant treatment cannot be definitely determined from the published literature; and (v) acknowledge that current definitions of 131I-refractory disease are suboptimal and do not represent definitive criteria to mandate whether 131I therapy should be recommended.

KEYWORDS:

adjuvant therapy; consensus; differentiated thyroid cancer; radioiodine-refractory thyroid cancer; remnant ablation

PMID:
30900516
DOI:
10.1089/thy.2018.0597

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center